| Date | Title | Description |
| 10.11.2023 | Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System. | Galway, Ireland. 2 November 2023. Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Re... |
| 10.11.2023 | Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind. | October 31, 2023. Cambridge, Massachusetts and London. Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, and Therakind Ltd (‘Therakind’), a UK-based speciality pharmaceutical company have entered into an agreement u... |
| 10.11.2023 | Artica Therapeutics Closes €12M Seed Investment to Develop Covalent Therapeutics for Autoimmune and Inflammatory Disorders. | Leiden, The Netherlands. 2 November, 2023. Artica Therapeutics B.V. (Artica), a biotechnology company unlocking the power of medicines with insurmountable binding characteristics, today announced it has raised €12 million in Seed financing.... |
| 10.11.2023 | Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy. | Munich, Germany. 9 November 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the enrolment of their first participant in the ... |
| 11.10.2023 | Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial. | Naperville, Illinois, USA. 9 October, 2023. Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exemption (IDE) appro... |
| 05.10.2023 | Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio. | Cambridge, Massachusetts, USA. 4 October 2023. Seroba’s portfolio company, Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partner... |
| 30.09.2023 | New expanded indication will increase home hemodialysis device options available to patients with end-stage kidney disease. | Beverly, Massachusetts, USA. 19 September 2023. Seroba’s portfolio company, Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it has submitted a 510(k) premarke... |
| 19.08.2023 | Quanta™ Announces Enrollment Completion in Home Run Study. | Beverly, Massachusetts, U.S.A. 17 August 2023. Seroba’s portfolio company, Quanta Dialysis Technologies®, today announced that it has completed enrollment of its Home Run study for at-home hemodialysis. The Home Run study is a prospective, ... |
| 05.08.2023 | Complement Therapeutics Appoints Dr Parisa Zamiri MD, as Chief Medical Officer. | Munich, Germany. 2 August 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, has announced the appointment of Dr Parisa Zamiri as its Chief Med... |
| 05.08.2023 | Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies. | Beverly, Mass., USA. 3 August, 2023. Quanta Dialysis System becomes first-in-class to perform three standard-of-care dialysis modalities in one device.
Quanta Dialysis Technologies®, a medical technology company committed to making kidney ... |
| 30.07.2023 | Palliare announces EU CE mark approval under new Medical Devices Regulation. | Galway, Ireland and Oceanside, CA, USA. 28 July, 2023. Seroba’s portfolio company, Palliare, a leading developer of advanced insufflation technologies, has received EU CE Mark certification under the new EU Medical Devices Regulation (MDR) ... |
| 15.06.2023 | Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b. | Paris, France. 31 May 2023. Seroba portfolio company, Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces... |
| 09.06.2023 | Perfuze Announces Appointment of New Chair of the Board. | Galway, Ireland. 9 June, 2023. Seroba portfolio company, Perfuze, a medical device company developing next-generation ”super-bore” catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami a... |
| 06.06.2023 | Endotronix Extends Positive Outcomes with 12-month Data Release from the SIRONA 2 Trial for Remote Heart Failure Management Using the Cordella Pulmonary Artery Sensor. | Lisle, Illinois, USA. 22 May 2023. Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive 12-month data from the SIR... |
| 18.04.2023 | Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases. | Munich, Germany. 17 April 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, today announced the completion of a €72 million Series A financing... |
| 05.04.2023 | Endotronix Announces Enrollment Completion of PROACTIVE-HF Pivotal Trial. | Lisle, Illinois, USA. 4 April 2023. Seroba’s portfolio company, Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced its PROACTIVE-HF pivotal study succ... |
| 07.03.2023 | Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia. | Cambridge, MA, USA. March 7, 2023. Shorla Oncology (‘Shorla’), a US-Ireland pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatme... |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter. | Galway, Ireland. 16 February 2023. Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FD... |
| 15.02.2023 | Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer. | Hamilton, ON, Canada and Boston, MA, USA. 13 February 2023. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) (“Fusion”), a clinical-stage oncology company focused on developing next-generation targeted alpha therapies (“TATs”) as precision medici... |
| 01.02.2023 | U.S. FDA Grants 510(k) Expanded Indication for Palliare’s EVA15 Insufflation Technology to Accommodate Higher Pressure Range. | 31 January 2023. Galway, Ireland and Oceanside, California, USA. Palliare, a leading developer of advanced insufflation technologies, has received an expanded 510(k) indication from the U.S. Food and Drug Administration for its EVA15 Insuff... |
| 01.02.2023 | Deciphex Secures €3.9m Funding to Boost Digital Pathology and AI Services. | 25 January 2023. Dublin, Ireland. Deciphex, a leading provider of pathology software and services, announced today a further €3.9m in funding bringing its full Series B round tally to €15m.
The additional investment, led by Seroba Life Sci... |
| 19.12.2022 | STORM Therapeutics announces closing of USD $30M Series B financing. | 14 December, 2022. Cambridge, England. STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, tod... |
| 07.12.2022 | STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study. | 23 November 2022, Cambridge, UK. STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces th... |
| 08.10.2022 | Endotronix Celebrates 400th Implant of Cordella™ Pulmonary Artery Pressure Sensor for Proactive, Remote Heart Failure Management | Lisle, Ilinois, USA. 30 September 2022. Seroba portfolio company, Endotronix, Inc., a privately-held digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced implantation of t... |
| 08.10.2022 | Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform. | Verona, Italy, 4 October, 2022. Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (... |
| 08.09.2022 | STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer. | Cambridge, England, 7 September 2022. Seroba portfolio company, STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other d... |
| 02.09.2022 | Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3. | Hamilton, Ontario, Canada and Boston, USA. 29 August 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that... |
| 04.08.2022 | Atlantic Therapeutics Announces the Appointment of Russell Medford MD, PhD as New US-Based Chairman. | Galway, Ireland and Boston, USA. 27 July 2021. Atlantic Therapeutics has announced the appointment of Russell Medford MD, PhD as Chairman. The addition of Dr Medford to the Board is a significant step to fulfill the potential of the INNOVO®... |
| 23.06.2022 | Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-2059, An Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1. | Hamilton, Ontario, Canada and Boston, USA. June 23, 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that ... |
| 22.06.2022 | Fusion Pharmaceuticals Presents Imaging Data From Cold Antibody Sub-Study In The Phase 1 Study Of FPI-1434 | Hamilton, Ontario, Canada and Boston, USA. 14 June 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pr... |
| 25.05.2022 | Endotronix Announces Positive Data from SIRONA 2 in Late-Breaking Clinical Trial Session | Lisle, Illinois, USA. 23 May 2022. Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive data from the SIRONA 2 clinical trial evaluating safet... |
| 13.04.2022 | Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors. | Cambridge, Mass., USA. 29 March 2022. Shorla Oncology (‘Shorla’), an Irish specialty pharmaceutical company, today announced the appointment of Dennis Purcell as Board Chairman. As a preeminent leader in the biotech industry, Purcell brings... |
| 27.01.2022 | Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study. | Lisle, Illinois, USA. 5 January 2022. Seroba portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administrat... |
| 27.01.2022 | Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development. | Hamilton, Ontario, Canada and Boston, Massachusetts, USA. 10 January, 2022. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, tod... |
| 25.11.2021 | Fusion Pharmaceuticals Appoints Mohit Rawat As President And Chief Business Officer | Hamilton, Canada and Boston, USA. 28 September 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appoin... |
| 04.06.2021 | Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility | Hamilton, Ontario, Canada. 3 June 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year le... |
| 03.03.2021 | Shorla Pharma Announces U.S. Industry Veteran Nicholas Holsman as Chief Commercial Officer. | Clomel, Tipperary, Ireland. 2 March 2021. Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-dep... |
| - | Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial | Lisle, Illinois. February 18, 2020. Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two ... |
| - | Novate Acquired By BTG for Up To $150m. | Dublin, Ireland. 7 Sept 2018. TG plc (LSE:BTG) (BTG) and Seroba’s portfolio company, Novate, today announced the signing of a definitive agreement in which BTG has acquired Novate for a $20m upfront payment with additional potential milesto... |
| - | PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study. | Milpitas, California & Dublin, Ireland. October 8, 2019. PQ Bypass Announces Unconditional IDE Approval from U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2)
Seroba’s portfolio company, PQ Bypass, Inc., a clinical-stage ... |
| - | Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes. | California, USA and Cambridge, UK. 14 October 2021.
STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform.
Exelixis, Inc. (Nasdaq: EXEL) and STORM ... |
| - | Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors. | Lisle, IL, USA. 2 March 2021. Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan De... |
| - | Heidi Zak, CEO of ThirdLove, joins INNOVO® in advisory role. | USA and Ireland. 10 November, 2020. Seroba’s portfolio company, Atlantic Therapeutics, has announced that Heidi Zak, co-founder and CEO of ThirdLove will take on an advisory role in the acceleration of the INNOVO® brand.
INNOVO® is a direc... |
| - | Fusion Pharmaceuticals Announces Pricing of Initial Public Offering. | Hamilton, Ontario and Boston. 25 June 2020. Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its ... |
| - | Quanta Wins Industrial Product Design 2018. | Alcester, UK. 1 October 2018. Quanta Dialysis Technologies Ltd (“Quanta”), a medical device company pioneering innovative haemodialysis products for dialysis patients, is pleased to announce that it has won the “Industrial Product Design of... |
| - | Palliare announces US FDA 510(k) clearance to extend the indications of its EVA15 insufflation technology for use in endoscopic surgery. | Galway, Ireland. 15 July 2021. Seroba portfolio company, Palliare, an emerging company with the vision to create a safer operating room, has announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capa... |
| - | Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia Treatment | Clonmel, Ireland. April 23, 2021. Seroba’s portfolio company, Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing... |
| - | Endotronix Closes Expanded Series D Round. | Lisle, Illinois & Dublin, Ireland. Oct 1, 2019. Seroba’s investee company, Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D fin... |
| - | Otsuka Medical Devices Acquires Veryan. | Dublin, Ireland. 14 December, 2018. Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a 100% subsidiary of Otsuka Holdings Co., Ltd., and Veryan Medical Ltd. (“Veryan”) have announced the completion of the acquisition of Veryan b... |
| - | Labcyte Sold to Beckman Coulter. | Dublin, Ireland. 30 January 2019. Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue.
Labcyte is best k... |
| - | CMS Approves Coverage for PQ Bypass TORUS 2 IDE Trial | Milpitas, California. 6 January 2020. Seroba’s portfolio company, PQ Bypass Inc, a medical device company bringing new advancements to the treatment of peripheral artery disease (PAD), has announced that it has received approval for coverag... |
| - | Quanta Raises $48 million in Series C Funding Round. | Alcester, Warwickshire, UK. 29 July 2019. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company developing a personal haemodialysis system (SC+) for patient use in the... |
| - | Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion’s Targeted Alpha Therapy (TAT) in Combination with Merck’s KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors... | Hamilton, Canada and Boston, USA. May 6, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has ente... |
| - | Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board | Hamilton, Ontario & Boston, Massachusetts. January 13, 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an invest... |
| - | Labcyte Partners with GP-write in Large-Scale Genomic Testing. | California, USA. 17 July, 2018. Labcyte Inc., today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing initial planning and coordination of efforts for the Genome P... |
| - | Fusion Pharmaceuticals Appoints New Chief Medical Officer | Hamilton, Ontario. 23 March 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers... |
| - | Prexton Acquired by Lundbeck for up to €905m. | Oss, The Netherlands & Dublin, Ireland. 16 March 2018. H. Lundbeck A/S (Lundbeck) and Seroba’s Investee Company, Prexton Therapeutics BV (Prexton), today announced the signing of a definitive agreement in which Lundbeck will acquire Pre... |
| - | FDA Approval for Endotronix Pivotal Trial. | Dublin, Ireland and Lisle, Illinois, USA. August 1, 2019. Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced it has recei... |
| - | Quanta Successfully Completes Pilot Treatments in France. | Alcester, UK. 25 April 2018. Seroba’s investee company Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions, has announced that it has successfully completed a c... |
| - | PQ Bypass Reports Positive 12-Month Results. | Milpitas, California. 28 June 2018. Results from the DETOUR I Trial evaluating the PQ Bypass DETOUR System for percutaneous bypass showed promising 12-month durability for patients with extremely long blockages in the superficial femoral ar... |
| - | Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Cancer Trial | Hamilton, Ontario and Boston. 10 December 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first ... |
| - | Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434. | Hamilton, Ontario and Boston. June 14, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation o... |
| - | Quanta Appoints New Chief Medical Officer | Alcester, UK, 4 Jan 2019: Seroba portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announced the Compan... |
| - | Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO® | GALWAY, Ireland. 6 February 2020. Seroba’s portfolio company, Atlantic Therapeutics, a global medical device manufacturer, today announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNO... |
| - | STORM Therapeutics Presents Breakthrough Data at RNA Epigenetics Conference. | Cambridge, UK. 18 September 2019. STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced today that Oliver Rausch, Chief Scientific Officer of STORM Therapeut... |
| - | STORM Therapeutics selects first-in-class clinical candidate targeting METTL3 | Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its... |
| - | First Patient Dosed in Fusion Phase I trial. | Boston, Massachusetts & Hamilton, Ontario. February 19, 2019. Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was d... |
| - | Seroba Leads $8M Series A Investment into Palliare | Galway, Ireland. 28 June 2021. Palliare, an emerging company with the vision to create a safer operating room, has announced the closing of an oversubscribed $8 million Series A funding round.
The round was led by leading European Life Sci... |
| - | Atlantic Therapeutics Secures FDA Approval. | Galway, Ireland. 13 November 2018. Seroba’s portfolio company, Atlantic Therapeutics, a global manufacturer of innovative, garment-based pelvic floor muscle strengthening and nerve stimulation products, has announced that the U.S. Food and ... |
| - | Shorla Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment. | Cambridge, Massachusetts, USA. 17 August, 2021. Seroba’s portfolio company, Shorla Pharma (‘Shorla’), a specialty pharmaceutical company and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry,... |
| - | Atlantic Therapeutics Raise €28M in Series B Funding. | Galway, Ireland. 7 January 2019. Atlantic Therapeutics, the medical technology company developing garment-based pelvic floor muscle strengthening and nerve stimulation devices treating the cause of bladder leaks, has announced that it has c... |
| - | Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors | Hamilton, ON and Boston. April 1, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donal... |
| - | Neurovascular Company Perfuze Raises €22.5M ($25M) Series A For New Stroke Treatment. | Galway, Ireland, February 7th, 2022. Perfuze, a medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, has closed a €22.5 million Series A investment rou... |
| - | INNOVO® Partners with Joan Lunden and Jamie Hess on Women’s Health Educational Initiative. | New York, USA. 14 October, 2021. Women’s pelvic health brand INNOVO, an FDA-cleared medical device that delivers perfect Kegels through electrical stimulation, is partnering with journalist and author, Joan Lunden and her daughter, wellness... |
| - | Seroba Invests in Storm Therapeutics. | Cambridge, UK. 20 May 2019. STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing... |
| - | Quanta provides compact dialysis systems to NHS to support increased need caused by COVID-19 pandemic | Alcester, Warwickshire, UK. 01 June 2020. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology innovation company, today announced that it has been proudly supporting the ongoing Nat... |
| - | New U.K. Study Offers Good News to Sufferers During World Continence Week | United Kingdom. 22 June 2020. A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash ... |
| - | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform. | Paris, France – 21st July 2021.
• Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases
• Funding led by Seroba Life Sciences and suppo... |
| - | FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy. | Dublin, Ireland. 9 September 2020. FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molec... |
| - | John S. Lipman Appointed as Quanta’s President, North America. | Alcester, Warwickshire, UK. 24 November 2020. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology company developing innovative dialysis products and services, has announced the app... |
| - | Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System | Lisle, Illinois. November 18, 2019. Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Co... |
| - | Quanta SC+ confirmed as safe and easy to use. | Alcester, Warwickshire, UK. 15 April 2019. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in... |
| - | Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System | Alcester, England & Beverly, Mass., USA. June 23, 2021. Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today t... |
| - | Veryan Receives PreMarket Approval. | Horsham, UK. 05 October 2018. Seroba Investee, Veryan Medical Ltd, today announced that the Company has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food & Drug Administration (FDA). The dev... |
| - | Fusion Raises $105m in Series B Financing. | Hamilton, Ontario and Dublin, Ireland. April 2nd 2019. Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced ... |
| - | Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3. | Hamilton, Ontario and Boston, Massachusetts. July 28, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced tha... |
| - | Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies. | Hamilton, Ontario and Boston, 2 November 2020. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration ... |
| - | Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen. | Hamilton, Canada and Boston, USA. March 2, 2021. Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered... |
| - | PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device. | MILPITAS, California. September 2, 2020. PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD), announced today that they received Breakthrough Device designation from... |
| - | PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial. | MILPITAS, Calif. November 12, 2020. Seroba’s portfolio company, PQ Bypass, Inc, a medical device pioneer bringing new advancements to the treatment of complex peripheral artery disease (PAD), announced promising long-term safety and effecti... |
| - | PQ Bypass Sold to Endologix | Dublin, Ireland. 14 April 2021. Seroba’s portfolio company, PQ Bypass Inc., a medical device pioneer advancing the treatment of complex peripheral artery disease (PAD), has been acquired by Endologix, a global medical device company wholly ... |
| - | Endotronix Celebrates 100th Implant Of The Cordella™ Pulmonary Artery Pressure Sensor For Proactive, Remote Management Of Heart Failure | Galway, Ireland and Lisle, IL, USA. March 23, 2021. Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced the 100th global implant of the Cordella Pulmonary ... |
| - | Atlantic Therapeutics appoints Susan Trent as new CEO, based in the United States. | Galway, Ireland. 14 July 2020. Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill the potential of the INNOVO® brand in the large and under-served... |
| - | PQ Bypass Announces $60M Financing. | Ireland and California, USA. January 08, 2019. Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), has entered into an agreement... |
| - | Endotronix Raises $45M Series D Financing. | Ireland and USA. 14 Sept 2018. Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million.
The round was led by LS... |
| - | Shorla Pharma Closes $8.3m Series A Funding Round | Dublin and Clonmel, Ireland. June 4, 2020. Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m. The financing was led by Seroba Life Sciences (‘Ser... |
| - | Doctors Perform ‘Bypass’ Without Surgery. | Little Rock, Arkansas. 2 March 2018. Seroba’s investee company, PQ Bypass was making eye-catching headlines in the USA this week. Arkansas Heart Hospital is the first U.S. hospital to perform the DETOUR procedure and the story was carried o... |
| - | Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch | Alcester, Warwickshire, UK. 8 January 2021. Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or “the Company”), a medical technology pioneer developing innovative dialysis products and services for the global market, t... |
| - | Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors | Boston, Massachusetts & Hamilton, Ontario. February 6, 2020. Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of P... |
| - | Novozymes acquires PrecisionBiotics Group. | Dublin, Ireland. 25 June 2020. Seroba’s portfolio company, PrecisionBiotics Group has been acquired by Novozymes.
Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health. Its products ... |
